Australia markets closed

Dyne Therapeutics, Inc. (DYN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.86+0.21 (+0.89%)
At close: 04:00PM EDT
23.68 -0.18 (-0.75%)
After hours: 06:28PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.04B
Enterprise value 1.94B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)22.33
Enterprise value/revenue N/A
Enterprise value/EBITDA -8.08

Trading information

Stock price history

Beta (5Y monthly) 0.95
52-week change 3108.37%
S&P500 52-week change 321.23%
52-week high 330.27
52-week low 36.40
50-day moving average 325.85
200-day moving average 315.16

Share statistics

Avg vol (3-month) 31.42M
Avg vol (10-day) 3816.88k
Shares outstanding 586.18M
Implied shares outstanding 686.18M
Float 852.67M
% held by insiders 10.55%
% held by institutions 186.51%
Shares short (28 Mar 2024) 48.08M
Short ratio (28 Mar 2024) 44.31
Short % of float (28 Mar 2024) 411.55%
Short % of shares outstanding (28 Mar 2024) 49.37%
Shares short (prior month 29 Feb 2024) 46.61M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-64.21%
Return on equity (ttm)-137.31%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -240.49M
Net income avi to common (ttm)-235.94M
Diluted EPS (ttm)-3.95
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)123.1M
Total cash per share (mrq)1.5
Total debt (mrq)27.41M
Total debt/equity (mrq)30.03%
Current ratio (mrq)2.53
Book value per share (mrq)1.49

Cash flow statement

Operating cash flow (ttm)-188.16M
Levered free cash flow (ttm)-104.23M